Recent investigations have converged on the overlap of glucagon-like peptide-1|GIP|GCGR activator therapies and dopamine communication. While GLP activators are commonly employed for treating type 2 diabetes, their unexpected consequences on reward circuits, specifically influenced by dopamine systems, are receiving significant focus. This article